DIA会员及用户请点击登录

登录

忘记用户 ID? or 忘记密码?

Not a Member?

创建账户并加入。

Menu 返回 Regulatory-Strategy

Regulatory Strategy

This track explores the various aspects relating to the implementation of European Regulatory Network Strategy, the EMA Regulatory Science Strategy, European Commission Pharmaceutical Strategy and the interface with the global regulatory advancements. It looks at novel therapies coming to the market with unprecedented speed, unmet medical need, patient centricity, building further capabilities in regulatory science, ongoing developments in biosimilars, medical devices and drug device combination, development support and the future of evidence as it relates to regulatory approvals. We will also look at how the regulatory framework in Europe will transform and focus on the balance between adaptability and sustainability, medicine access, manufacturing innovation and solutions for drug shortages.

Who is This Track Designed For?

Professionals involved in regulatory strategy, regulatory policy and intelligence, market access and HTA policy, project management, patients, academics and consultants

Register Now

DIA Europe 2022 Brochure

The online program is now available. Explore the rich content we offer across 10 thought leadership tracks. 

View Searchable Programme

Topic Leaders

Isabelle Stoeckert

Isabelle Stoeckert, PharmD

Head RA EMEA

Bayer AG, Germany

Henrik K. Nielsen

Henrik K. Nielsen, PhD, MBA, MSc

Vice President

Novo Nordisk A/S, Denmark

Featured Podcast

EU Regulatory Strategies Shaping and Shaped by Pandemic Response

COVID has demonstrated the importance of regulatory systems that ensure the safety and efficacy of therapeutic products as well as patient access to these products, especially in the complex network of healthcare, scientific, pharmaceutical, regulatory, and patient communities in Europe. “Regulators and industry have worked day and night over the last two years to bring vaccines and therapies forward. We know very clearly that sustainability of the system is an issue. More regulatory resources and simpler processes are desperately needed,” explains Isabelle Stoeckert, Bayer AG vice president and head of regulatory affairs for Europe, Middle East, and Africa. “Many countries have learned that reliance and collaboration between regulators is a really good thing. COVID-19 has really shown that,” suggests Henrik Nielsen, Novo Nordisk vice president of global regulatory sciences. “And I think this will stay, so we will see more reliance between regulatory sources, and we'll probably see increased use of different collaboration schemes around the world.”

Listen now

EU Regulatory Strategies Shaping and Shaped by Pandemic Response

Isabelle Stoeckert, PharmD
Henrik K. Nielsen, PhD, MBA, MSc

DIA Europe 2022 Highlights

It will provide updates on key developments on the GCP Renovation (ICH E6, ICH E8), Clinical Trial Regulation, the Clinical Trial Information System, data submission, transparency, navigating ethical approval, study design in the digital age, innovative clinical trial designs (umbrella and platform trials, patient centricity), digital tools in development and other hot topics. It should be a must-attend for optimising development programmes and identifying cost savings through efficiency and innovation.


Explore All Tracks

获得信息并保持参与

不要错失任何机会——请加入我们的邮件列表,了解DIA的观点和事件。